The FDA has granted Breakthrough Therapy designation for litifilimab for the treatment of cutaneous lupus erythematosus, a chronic autoimmune skin disease.
Biogen (NASDAQ:BIIB) executives said the company ended 2025 “slightly above the upper end” of its guidance, pointing to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results